GZero Therapeutics

1
G-Zero Therapeutics
Contact John Chant, 650-307-7770
chant_john_at_hotmail.com
2
Protection BEFORE Treatment
Models Radioprotection and Chemoprotection
Clinical Oncology Supportive Care
3
Treating Bone Marrow Suppression
Stem Cell
G-Zero PharmacoQuiescence (PQ)
Multi-potent Progenitors
Common Lymphoid Progenitor
Common Myeloid Progenitor
Megakaryocyte-Erythroid Prog.
Granulocyte-Monocyte Prog.
T-cells
B-cells
Granulocytes
Erythrocytes
Platelets
Macrophages
EPO
Neupogen
Unmet
Unmet
4.3B
4.6B
Neumega (Wyeth)very minor product
4
All Lineages Protected
Nadir blood counts 21 days after 7.5 Gy of TBI
60
600
4.0
2.0
0.8
45
450
3.0
1.5
0.5
Percent
103 / uL
103 / uL
103 / uL
103 / uL
30
300
2.0
1.0
0.3
15
150
1.0
0.5


Total White Blood Count
Hematocrit
Platelets
Lymphocytes
Myeloid Cells
Untreated (n4)
Treated (n5)
9
5
Technology

• Proprietary small molecule therapeutics that
  prevent bone marrow suppression
• Novel method no other small molecule does this
• Intellectual property from Sharpless Lab

6
Applications

• Protect bone marrow during chemotherapy for
  cancer
• 5B market per year
• Government sponsored market radiation mitigation
• 200-250M contracts available so stockpile
• Generous non-dilutive financing SBIR, etc.
• G-Zero Technology is Demonstrably Superior to
  Existing Treatments

7
Current Status

• Research operations housed in Lineberger
  Comprehensive Cancer Center
• Subcontractors/Consultants in place
• Non-dilutive financing in place

8
Founders
Norman Ned Sharpless , MD Clinical
Oncologist UNC Medical School, Lineberger
Comprehensive Cancer Center Kwok-kin Wong, MD Ph
D Clinical Oncologist Dana Farber Cancer
Institute, Harvard Medical School John Chant Ph
D President, G-Zero Therapeutics Former
Harvard University, CuraGen/454, Genentech
Oncology
9
Needs

• To achieve proof of concept trial in humans for
  chemoprotection and approval for radioprotection
  5M/2-3 years
• To achieve NDA for chemoprotection 10M
  additional/additional 1-2 years
• budget numbers do not account for government
  funding

10
G-Zero Therapeutics
Contact John Chant, 650-307-7770
chant_john_at_hotmail.com